Expression of the von Hippel-Lindau-binding protein-1 (Vbp1) in fetal and adult mouse tissues.
暂无分享,去创建一个
[1] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[2] Christopher A. Friedrich. Von Hippel‐Lindau Syndrome , 1999 .
[3] D. Mukhopadhyay,et al. The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways* , 1997, The Journal of Biological Chemistry.
[4] P. Green,et al. Characterization of the gene (VBP1) and transcript for the von Hippel-Lindau binding protein and isolation of the highly conserved murine homologue. , 1997, Genomics.
[5] D. Mukhopadhyay,et al. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity , 1997, Molecular and cellular biology.
[6] J M Ward,et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[7] A. Kibel,et al. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. , 1997, Human pathology.
[8] Y. Miyagi,et al. VON HIPPEL–LINDAU TUMOUR SUPPRESSOR GENE. LOCALIZATION OF EXPRESSION BY IN SITU HYBRIDIZATION , 1996, The Journal of pathology.
[9] W. Kaelin,et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[10] R. Klausner,et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[11] J. Nadeau,et al. Epistatic control of non-Mendelian inheritance in mouse interspecific crosses. , 1996, Genetics.
[12] W. Kaelin,et al. Expression pattern of the von Hippel-Lindau protein in human tissues. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[13] O. Hino,et al. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. , 1996, Cancer research.
[14] G. Martiny-Baron,et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. , 1996, Cancer research.
[15] P. Schofield,et al. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. , 1996, Human molecular genetics.
[16] R. Ohlsson,et al. Allele-specific in situ hybridization (ASISH) analysis: a novel technique which resolves differential allelic usage of H19 within the same cell lineage during human placental development. , 1996, Development.
[17] L. Liotta,et al. von Hippel-Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. , 1996, Human pathology.
[18] G. Breier,et al. Coordinate expression of vascular endothelial growth factor receptor‐1 (fit‐1) and its ligand suggests a paracrine regulation of murine vascular development , 1995, Developmental dynamics : an official publication of the American Association of Anatomists.
[19] B. Ponder,et al. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. , 1995, Journal of medical genetics.
[20] D. Duan,et al. Inhibition of transcription elongation by the VHL tumor suppressor protein , 1995, Science.
[21] William Arbuthnot Sir Lane,et al. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II , 1995, Science.
[22] A. Kibel,et al. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.
[23] F. Duh,et al. Expression of the Von Hippel-Lindau Tumor Suppressor Gene, VHL, in Human Fetal Kidney and During Mouse Embryogenesis , 1995, Molecular Medicine.
[24] K. Plate,et al. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. , 1995, Cancer research.
[25] B. Seizinger,et al. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. , 1994, American journal of human genetics.
[26] R. Hené,et al. Von Hippel-Lindau disease: new strategies in early detection and treatment. , 1994, The American journal of medicine.
[27] T. Sugimura,et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. , 1994, Cancer research.
[28] Y Kubota,et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.
[29] J. Brooks,et al. Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.
[30] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[31] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[32] F. Biddle. Segregation distortion of X-linked marker genes in interspecific crosses between Mus musculus and M. spretus. , 1987, Genome.
[33] A. Sakurai,et al. [von Hippel-Lindau syndrome]. , 2001, Ryoikibetsu shokogun shirizu.
[34] 麻生 悌二郎. Elongin (SIII) : a multisubunit regulator of elongation by RNA polymerase II , 1996 .
[35] W. Linehan,et al. Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: Correlations with phenotype , 1995, Human mutation.
[36] A. Lindau. Studien Uber Kleinhirncysten. Bau, Pathogenese und Beziehungen zur Angiomatosis Retinae , 1926 .